Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02715193 · ClinicalTrials.gov registry record · Phase 1
Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus
A Phase 1 study, sponsored by REMD Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT02715193 is a Phase 1 study that has completed, run by REMD Biotherapeutics. The registered enrollment target is 21 participants.
The verdict
NCT02715193, a Phase 1 study, has completed, sponsored by REMD Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a randomized, placebo-controlled, double-blind study to evaluate safety, tolerability and pharmacodynamics of REMD-477 in subjects who have Type 1 diabetes and are currently receiving insulin treatment. This proof of concept study will determine whether glucagon receptor blockade using a single dose REMD-477 can improve short-term glucose homeostasis in people with Type 1 diabetes.
Interventions
- BIOLOGICAL Placebo Comparator
- BIOLOGICAL REMD-477
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02715193
The ClinicalTrials.gov registry entry for NCT02715193 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is REMD Biotherapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT02715193 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02715193 about?
NCT02715193 is a clinical study titled "Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus". This is a randomized, placebo-controlled, double-blind study to evaluate safety, tolerability and pharmacodynamics of REMD-477 in subjects who have Type 1 diabetes and are currently receiving insulin treatment. This proof of concept study will determine whether glucagon receptor blockade using a sin...
What is the current status of trial NCT02715193?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2016-03. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02715193?
The interventions under investigation include: Placebo Comparator (BIOLOGICAL), REMD-477 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02715193?
This trial is sponsored by REMD Biotherapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.